Compare ANET & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANET | JNJ |
|---|---|---|
| Founded | 2004 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.5B | 542.4B |
| IPO Year | 2014 | 2003 |
| Metric | ANET | JNJ |
|---|---|---|
| Price | $162.31 | $239.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 20 |
| Target Price | $175.18 | ★ $238.20 |
| AVG Volume (30 Days) | ★ 7.7M | 7.4M |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 2.36% |
| EPS Growth | 23.32 | ★ 90.50 |
| EPS | 0.80 | ★ 2.14 |
| Revenue | ★ $9,005,700,000.00 | N/A |
| Revenue This Year | $29.10 | $6.63 |
| Revenue Next Year | $21.80 | $7.43 |
| P/E Ratio | $218.20 | ★ $108.08 |
| Revenue Growth | ★ 28.60 | N/A |
| 52 Week Low | $97.14 | $150.73 |
| 52 Week High | $179.80 | $251.71 |
| Indicator | ANET | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 59.01 |
| Support Level | $139.00 | $233.83 |
| Resistance Level | $163.81 | $244.80 |
| Average True Range (ATR) | 7.38 | 4.60 |
| MACD | 0.52 | 0.22 |
| Stochastic Oscillator | 52.05 | 87.09 |
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.